Program 02: Gynecologic Cancers

项目02：妇科癌症

• 批准号: 10332564
• 负责人: URSULA Anne MATULONIS
• 金额: $ 4.2万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-10 至 2026-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10332564
• 关键词: Academy; Advanced Development; Age; Area; Award; Biological Models; CA-125 Antigen; Cancer Center; Cancer Center Support Grant; Caring; Catchment Area; Cervical; Clinical; Clinical Trials; Collaborations; Combined Vaccines; Correlative Study; Dana-Farber Cancer Institute; Department of Defense; Development; Diagnosis; Diagnostic Procedure; Direct Costs; Disease; Early Diagnosis; Endometrial; Endometrial Carcinoma; Environment; Faculty; Fellowship Program; Funding; Germ Cell Cancers; Germ cell tumor; Goals; Grant; Histology; Human; Immunotherapy; Incidence; Infrastructure; Institution; Investigation; K-Series Research Career Programs; Laparotomy; Leadership; Link; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant Vaginal Neoplasm; Malignant neoplasm of cervix uteri; Malignant neoplasm of ovary; Malignant neoplasm of vulva; Massachusetts; Mentors; Mirza; Mission; Mucinous; Mutate; Mutation; Operative Surgical Procedures; Organoids; Outcome; Ovarian; PD-1 inhibitors; Paper; Patient-Focused Outcomes; Peer Review Grants; Pharmaceutical Preparations; Poly(ADP-ribose) Polymerases; Pregnancy; Prevention; Process; Publishing; Ras/Raf; Recommendation; Research; Research Personnel; Research Training; Resistance; Resource Sharing; SECTM1 gene; Science; Scientist; Screening for cancer; Skates; Strategic Planning; Structure; Suggestion; Surgeon; Surgical Management; System; Teacher Professional Development; Techniques; Testing; Training; Translational Research; Translations; Tumor Immunity; Vaccines; Vagina; Vulva; Woman; anticancer research; biomarker discovery; cancer prevention; cancer risk; cancer surgery; career; career development; combinatorial; community engagement; diagnostic technologies; improved; inhibitor; inter-institutional; investigator-initiated trial; member; minimally invasive; next generation; novel strategies; novel therapeutic intervention; oncology program; pre-clinical; prognostic method; programs; racial disparity; radical hysterectomy; resistance mechanism; response; restoration; screening; surgical disparities; translational scientist; treatment program; trend; working group

Gynecologic Cancers Program Project Summary / Abstract The mission of the Gynecologic (Gyn) Cancers Program is to improve patient outcomes by developing novel strategies for early detection, therapy, and prevention through integrated translational research across the consortium. A related mission is to train and educate the next generation of translational researchers, clinical trialists, outcomes researchers, and basic scientists who focus on Gyn cancers. The Program encompasses investigation of all Gyn cancers including ovarian, endometrial, cervical, vaginal, vulvar, and germ cell cancers as well as gestational trophoblastic disease. Moreover, we respond to the increasing incidence of endometrial cancer (EnCa) in our catchment area (Massachusetts) as well as racial disparities in diagnosis and treatment of cervical cancer and EnCa in Massachusetts. A previous DF/HCC Program in Gyn Cancers was not included in the last CCSG renewal (2016); the current Program is thoroughly revamped. Its 59 members (47 primary and 12 secondary) represent five DF/HCC institutions and 6 academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $2.1 million in direct costs from the NCI and $1.2 million from other sponsors. During the current funding period, primary Program members published 629 cancer-relevant papers. Of these, 20% were inter- institutional, 27% were intra-programmatic, and 34% were inter-programmatic collaborations between two or more DF/HCC members. For the next CCSG funding period, the Program’s Specific Aims are to: 1) Develop and implement early detection, prevention, diagnostic, and prognostic methods for Gyn cancers in Massachusetts and across the US; 2) Develop and advance novel therapeutic strategies for Gyn cancers; and 3) Educate and mentor the next generation of leaders for Gyn Cancers through fellowship programs, junior faculty development, and placement of junior faculty on national committees. These goals align perfectly with the DF/HCC strategic plan and will require the full suite of CCSG components: shared resources, collaborative infrastructure, an effective system for clinical trial review and conduct, and structured processes for community engagement and cancer research training.

妇科癌症计划 项目概要/摘要 妇科 (Gyn) 癌症计划的使命是通过开发新的药物来改善患者的治疗结果 通过跨领域的综合转化研究进行早期检测、治疗和预防的策略 财团。一个相关的使命是培训和教育下一代转化研究人员、临床研究人员 专注于妇科癌症的试验者、结果研究人员和基础科学家。该计划包括 对所有妇科癌症的调查，包括卵巢癌、子宫内膜癌、宫颈癌、阴道癌、外阴癌和生殖细胞癌 以及妊娠滋养细胞疾病。此外，我们应对子宫内膜异位症发病率的增加 我们的学区（马萨诸塞州）的癌症（EnCa）以及诊断和治疗方面的种族差异 马萨诸塞州的宫颈癌和 EnCa。 之前的妇科癌症 DF/HCC 计划未包含在上次 CCSG 更新（2016 年）中；当前的 计划已彻底修改。其 59 名成员（47 名主要成员和 12 名二级成员）代表 5 个 DF/HCC 机构和6个学术部门。 2019 年，该计划经同行评审的赠款资金为 NCI 的直接费用为 210 万美元，其他赞助商的直接费用为 120 万美元。本次融资期间 在此期间，主要计划成员发表了 629 篇癌症相关论文。其中，20%是内部人士 机构间合作，27% 是项目内合作，34% 是两个或多个项目之间的项目间合作 更多 DF/HCC 成员。 对于下一个 CCSG 资助期，该计划的具体目标是： 1) 尽早制定和实施 马萨诸塞州及各地妇科癌症的检测、预防、诊断和预后方法 美国； 2) 开发和推进妇科癌症的新治疗策略； 3) 教育和指导 通过奖学金计划、初级教师发展和培养下一代妇科癌症领导者 将初级教师安置在国家委员会中。这些目标与 DF/HCC 战略计划完美契合 并且需要全套 CCSG 组件：共享资源、协作基础设施、有效的 临床试验审查和实施系统，以及社区参与和癌症的结构化流程 研究培训。